Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers

Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta

Research output: Contribution to journalArticle

Abstract

In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.

Original languageEnglish
Pages (from-to)139-143
Number of pages5
JournalTumori
Volume101
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

    Fingerprint

Keywords

  • Hepatocellular carcinoma
  • MET
  • Second-line treatment
  • Tivantinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Rimassa, L., Santoro, A., Daniele, B., Germano, D., Gasbarrini, A., Salvagni, S., Masi, G., Abbadessa, G., Lamar, M., Goldberg, T., & Porta, C. (2015). Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers. Tumori, 101(2), 139-143. https://doi.org/10.5301/tj.5000217